Advertisement
Screener

IDEXX LABORATORIES INC /DE (IDXX) Overview

IDEXX LABORATORIES INC /DE (IDXX) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 4.27; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 3.47; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 3.40; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 3.63; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$479.46$531.82$589.90$654.31$725.76$805.012025-11-062026-11-06$308.41$373.65$452.69$548.44$664.46$805.012021-11-082026-11-06$103.10$155.52$234.58$353.83$533.70$805.012016-11-072026-11-06$13.03$29.73$67.82$154.71$352.91$805.012006-11-062026-11-06$0.80$3.18$12.69$50.62$201.86$805.011991-06-212026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$675.90
Previous close
$533.44
Change
$142.46
Change (%)
26.71%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

IDXX
-21.15%
S&P 500
(m)

1 year

IDXX
-15.40%
S&P 500
(m)

3 years

IDXX
+21.99%
S&P 500
(m)

5 years

IDXX
-15.27%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 4.27

2.883.273.664.064.4531 Mar 2025: estimate (m); actual 2.9631 Mar 2025(m)30 Jun 2025: estimate (m); actual 3.6330 Jun 2025(m)30 Sept 2025: estimate (m); actual 3.4030 Sept 2025(m)31 Mar 2026: estimate (m); actual 3.4731 Mar 2026(m)30 Jun 2026: estimate (m); actual 4.2730 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)4.27(m)(m)
1 Jan 202631 Mar 2026(m)3.47(m)(m)
1 Jul 202530 Sept 2025(m)3.40(m)(m)
1 Apr 202530 Jun 2025(m)3.63(m)(m)
1 Jan 202531 Mar 2025(m)2.96(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 13.08

7.959.2810.6111.9313.2631 Dec 2021: estimate (m); actual 8.6031 Dec 2021(m)31 Dec 2022: estimate (m); actual 8.0331 Dec 2022(m)31 Dec 2023: estimate (m); actual 10.0631 Dec 2023(m)31 Dec 2024: estimate (m); actual 10.6731 Dec 2024(m)31 Dec 2025: estimate (m); actual 13.0831 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)13.08(m)(m)
1 Jan 202431 Dec 2024(m)10.67(m)(m)
1 Jan 202331 Dec 2023(m)10.06(m)(m)
1 Jan 202231 Dec 2022(m)8.03(m)(m)
1 Jan 202131 Dec 2021(m)8.60(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 1.22B ■ Earnings 0.34B — Profit margin 27.82%

-0.15B21.8%0.36B24.1%0.86B26.5%1.36B28.8%30 Sept 2025: revenue 1.11B; earnings 0.27B; profit margin 24.85%30 Sept 202531 Dec 2025: revenue 1.09B*; earnings 0.25B*; profit margin 22.76%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 1.14B; earnings 0.28B; profit margin 24.41%31 Mar 202630 Jun 2026: revenue 1.22B; earnings 0.34B; profit margin 27.82%30 Jun 2026

31 Dec 2025 ■ Revenue 4.30B ■ Earnings 1.06B — Profit margin 24.62%

-0.52B19.2%1.26B21.3%3.04B23.5%4.82B25.6%31 Dec 2022: revenue 3.37B; earnings 0.68B; profit margin 20.17%31 Dec 202231 Dec 2023: revenue 3.66B; earnings 0.85B; profit margin 23.08%31 Dec 202331 Dec 2024: revenue 3.90B; earnings 0.89B; profit margin 22.78%31 Dec 202431 Dec 2025: revenue 4.30B; earnings 1.06B; profit margin 24.62%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$675.90(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$675.90High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning IDXX

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$1.14B
Profit margin
25.03%
Return on assets · 12 month
33.65%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
11.00K
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
508.85K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
2.29%*
Total return · month
-3.88%*
Total return · quarter
-0.46%*
Total return · half year
-4.46%*
Total return · year to date
-21.15%*
Total return · 1 year
-15.40%*
Total return · 3 years
21.99%*
Total return · 5 years
-15.27%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$4.55B
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
27.90%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

IDEXX LABORATORIES INC /DE Overview

View more →

(m)

(m)

SEC CIK
874716
Industry (SIC)
2835 In Vitro & In Vivo Diagnostic Substances
Country of operation
United States
Business address
ONE IDEXX DRIVE, WESTBROOK, Maine, 04092-2041, United States
Fiscal year end
1231
Phone
2075560300

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lantheus Holdings, Inc. (LNTH)United States$6.510B26.31
NEOGEN CORP (NEOG)United States$2.979B-247.49
Celldex Therapeutics, Inc. (CLDX)United States$2.471B-9.72
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10